strong buy agressive - 500 Beiträge pro Seite

eröffnet am 17.06.01 15:27:53 von
neuester Beitrag 31.08.01 23:11:28 von


Beitrag schreiben

Begriffe und/oder Benutzer

 

Avatar
17.06.01 15:27:53
Kursziel (12m):$17
Widerstand: $11
Unterstützung: $8



U.S. Bancorp Piper Jaffray Initiates Coverage of HBIO with a Strong Buy Rating

BOSTON, June 15 /PRNewswire/ -- U.S. Bancorp Piper Jaffray Senior Biopharmaceuticals: Drug Discovery and Suppliers Analyst Tom Hancock today initiated coverage of Harvard Bioscience, Inc. (Nasdaq: HBIO) (8.15, ) with a Strong Buy rating and a 12-month price target of 17, based on a PEG ratio of 1.1 applied to our estimated three-year earnings-per-share growth rate of 40 percent and our fiscal earnings-per-share estimate of 0.38. Harvard Bioscience is a leading supplier of enabling tools for the biopharmaceutical industry. Harvard`s focus on addressing major obstacles in the drug development process has led the company into markets centered, as a result of acute industry demand, in the areas of drug discovery research and preclinical pharmacology/toxicology. Harvard Bioscience sells more than 1,000 products to more than 5,000 customers worldwide.

"We believe Harvard Bioscience is a leader in this market, a position it is leveraging by actively acquiring many of the smaller players in the space and consolidating its position," said Hancock. "Further growth potential comes from new technologies that eliminate or minimize the role of animals in such testing, which benefit from the broad desire of the industry to replace costly animal screening with in vitro assays whenever possible."

In his report, Hancock states that over the past several years, Harvard has made several key acquisitions in the drug discovery industry to expand the company`s product offerings in high growth areas. Harvard has moved into rapidly growing markets including protein sample preparation, proteomics and drug target validation and screening, most recently with the acquisitions of AmiKa and Union Biometrica. "In our opinion, the company`s ability to successfully integrate new technologies addressing growth markets differentiates this supplier, and makes it an attractive investment opportunity," said Hancock.

"We believe that Harvard Bioscience`s current strategy -- combining a technology base in key areas of the biomedical supplies market with strategic acquisitions in high growth areas -- will be rewarded by exemplary financial performance over the next several years," said Hancock. "Recent acquisitions should propel revenue growth to an average of 35 percent over the next couple years and we expect earnings-per-share growth to parallel or exceed revenue growth. Based on these projections, we believe Harvard shares currently trade at a significant discount to other profitable life science suppliers."

U.S. Bancorp Piper Jaffray, a subsidiary of Minneapolis-based U.S. Bancorp (NYSE: USB), provides a full range of investment products and services to businesses, institutions and individuals. The company`s investment banking business has grown exponentially in the last several years by focusing on the needs of growth companies in the health care, technology, financial institutions, consumer and industrial growth sectors. U.S. Bancorp Piper Jaffray has a national reputation for its expertise in fundamental research and equity and debt financing. U.S. Bancorp offers a comprehensive range of financial solutions through U.S. Bank, First American Asset Management, U.S. Bancorp Libra Investments and U.S. Bancorp Piper Jaffray. Securities products and services offered through U.S. Bancorp Piper Jaffray, Inc., member SIPC and NYSE, Inc., a subsidiary of U.S. Bancorp.

Some or all of the following hedges may apply. () U.S. Bancorp Piper Jaffray, Inc., makes a market in the company`s securities. () An U.S. Bancorp Piper Jaffray, Inc., officer, director or other employee is a director and/or officer of the company. () Within the past three years, U.S. Bancorp Piper Jaffray, Inc., was managing underwriter of an offering of, or dealer manager of a tender offer for, the company`s securities of an affiliate. Additional information is available upon request. Not FDIC Insured. No Bank Guarantee. May lose value.

This material is based on data obtained from sources we deem to be reliable it is not guaranteed as to accuracy and does not purport to be complete. This information is not intended to be used as the primary basis of investment decisions. Because of individual client requirements, it should not be construed as advice designed to meet the particular investment needs of any investor. It is not a representation by us or an offer or the solicitation of an offer to sell or buy any security. Further, a security described in this release may not be eligible for solicitation in the states in which the client resides. U.S. Bancorp Piper Jaffray individual officers, employees, or members of their families may own securities mentioned and may purchase or sell those securities in the open market or otherwise. In the United Kingdom, this report may only be distributed or passed on to persons of the kind described in Article 11 (3) of the Financial Services Act of 1986 (Investment Advertisements) (Exemptions) Order 1996 (as amended by the Financial Services Act 1986 Investment Advertisements) (Exemptions Order 1997).

Nondeposit investment products are not insured by the FDIC, are not deposits or other obligations of or guaranteed by U.S. Bank National Association or its affiliates, and involve investment risks, including possible loss of the principal amount invested. Securities products and services are offered through U.S. Bancorp Piper Jaffray Inc., member SIPC and NYSE, Inc., a subsidiary of U.S. Bancorp. (5/99-0679)

U.S. Bancorp Piper Jaffray Inc. is a member of the National Association of Securities Dealers, CRD number 665.

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X18415725
Avatar
18.06.01 10:04:09
Look-up gerade ausgelaufen. Vorsicht !! Ein strong buy zu diesem Zeitpunkt ist wohl mehr als eindeutig.

Könnten sich dadurch aber hervorragende Einstiegskurse unter 7$ ergeben.




Mfg bigtime
Avatar
25.08.01 12:07:55
Woodawork Investor stuft HBIO von agressive buy auf accumulate herunter. Das 12 Monatskursziel von 17$ wird beibehalten.
Den Kaufempfehlungen von U.S. Bancorp Piper Jaffray und Woodawork Investor schloss sich Dain Rauscher mit zweimaligen strong buy an.

Die Unterstützung bei 8$ hat gehalten.
Der Widerstand bei 11$ wurde, wenn auch nicht unter hohen
Umsätzen, gebrochen.
Avatar
31.08.01 18:18:32
WOODAWORK INVESTOR empfiehlt HBIO im Auge zu behalten. Stark ansteigendes Volumen
Avatar
31.08.01 19:07:47
gepostet bei 12.70$
aktuell: 13.40$

MFG:

Woodawork Investor
Avatar
31.08.01 23:11:28
Hallo Woodawork,

schau doch mal in den Postings der letzten vier Wochen in meinem Thread zu Integra Lifesciences nach. Dort habe ich HBIO bei 10$ als Kauf empfohlen. Bin selber gut investiert und freue mich heute über weiter 14% Kursgewinn auf 14,20$. In meinen Augen ist HBIO eine wahre Perle, die über ein absolut sicheres Geschäft mit tollen Margen verfügt und langsam von den Analysten entdeckt wird, wie die Kaufempfehlung von Piper Jaffray in der vergangenen Woche zeigt. Mein Kursziel bis Jahresende sind 17$. Da HBIO aber in den nächsten Jahren um durchschnittlich 35-40% im Gewinn wachsen dürfte ist die Aktie eine klare langfristige Anlage

Grüße Kurspotenzial


Beitrag zu dieser Diskussion schreiben


Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
hier
eine neue Diskussion.